The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

An analysis reveals a spike in pro-Russian disinformation networks surrounding the attempt to oust the European Commission ...

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and ...

WASHINGTON] Crypto companies and advocates of digital assets boosted their lobbying this year to ensure passage of landmark ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who could benefit.

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...